



Prior Authorization Approval Criteria
Department of Pharmacy Services

Generic Name: selegiline

Brand Name: Zelapar Orally Disintegrating tablets

Medication Class: Monoamine Oxidase Type-B Inhibitor

FDA Approved Uses: Adjunct in the management of patients with Parkinson's disease being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy.

Available Dosage Forms: 1.25mg tablet

Usual Dose: 1.25mg once a day to start, may be increased to 2.5mg once a day after 6 weeks.

Duration of Therapy: Indefinite

Approximate monthly cost (based on AWP 2006): \$140.40-\$280.80 for 1.25mg-2.5mg/day

Criteria for Use: *(bullet points below are all inclusive unless otherwise noted)*

- Clinically documented Parkinson's disease.
- Patient must currently be receiving treatment with levodopa/carbidopa.
- Patient must be exhibiting deterioration in quality of their response to levodopa/carbidopa therapy.
- Failed/intolerant to the conventional selegiline tablet.

Contraindications:

- Known hypersensitivity to any formulation of selegiline or any inactive ingredients of Zelapar.
- Concurrent use with the following drugs:
(14 days should elapse between discontinuation/initiation of Zelapar and initiation/discontinuation of any of the following)
 - Meperidine
 - Tramadol
 - Methadone
 - Propoxyphene
 - Dextromethorphan

Not Approved if:

- Does not meet the above stated criteria.
- Have any contraindications to the use of selegiline.



Special Considerations:

- There is no evidence from controlled studies that Zelapar has any beneficial effect in the absence of concurrent levodopa therapy.
- There is no evidence that dose greater than 2.5mg per day have any additional benefit, and should be avoided due to the potential of increased risk of adverse events since selegiline loses selectivity for MAO-B receptors at higher doses.

P&T Approval: _____ Date: _____